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Previous research has often seen alliances as a mechanism used by disadvantaged firms to 
seek new capabilities. But are alliances an effective dynamic capability? We find that less 
competent firms can use alliances to access new technologies, but more competent firms are 




Dynamic capabilities are the antecedent organizational and strategic routines by which 
managers alter their source base to generate new value-creating strategies (Eisenhardt and Martin, 
2000). In this perspective, the ability of the firm to create and manage new alliances in order to 
explore and eventually internalize new technologies in presence of discontinuous technological 
change is considered a dynamic capability.  
We ask two related questions on the effectiveness of alliances as mechanisms of reducing 
technology gaps. Corresponding to search, we test whether alliances allow less technologically 
endowed firms to enter a new technology faster. Under internalization, we study whether existing 
technological competences affect a firms' ability to integrate and retain the new technologies 
explored through alliances. We develop hypotheses based on the received theory and evidence on 
alliances as dynamic capabilities. Although previous work has investigated the role of different 
types of alliances in distinct stages of the product development process (Rothaermel and Deeds, 
2004), to our knowledge less attention has been paid to the distinction between the creation of an 
alliance and the subsequent eventual integration of the underlying technology. Research on the 
distinction between these two processes can yield important implications for the literatures on 
dynamic capabilities as well as strategic alliances. 
In order to answer these questions and test our hypotheses, we study the case of US and 
European pharmaceutical firms responding to the biotech revolution from the 1980s through the 
end of 1990s.   
 
THEORY AND HYPOTHESES 
 
Previous literature identifies the relative roles of different modes of investments. When it 
comes to development of new technology, firms face significant challenges internally due to 
inertia and the inertness of their routines. Alliances can then be a mechanism to break out of local 
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search constraints, and as such, they are more likely to be used when the firm is pursuing 
competences that are technologically distant. On the other hand, such an argument runs counter to 
the resource based view which suggests that firms need to own inimitable resources or 
capabilities in order to possess a competitive advantage. Specifically, it ignores the potentially 
significant firm-specific and path dependent effects of existing technological competences.  
In order to further examine these arguments, we break down the advantages of 
technologically proximal firms into superior technology search and superior technology 
internalization and then examine the implications of alliance strategies for each. Superior search 
is related to the capability to identify a relevant new technology and select the alliance partner to 
acquire that technology. Superior internalization requires learning from the alliance partner in 
order to access the new technology (Lane and Lubatkin, 1998) and integrate it into the existing 
base of competence within the firm (Helfat and Raubitschek, 2000). This is a necessary pre-
condition to develop new successful products and processes from the technology accessed 
through the alliance. By decomposing the nature of alliance advantages and of the underlying 
dynamic capabilities, we can examine if alliances are more effective in neutralizing some of these 
advantages than others. We discuss each one of these in turn. 
 
Alliances and Technology Search 
 
Consider two kinds of firms competing in a environment of disruptive technology: one 
firm has developed new capabilities internally and is therefore, closer to the new technologies, 
while the other is relatively distant from the new technologies. Firms technologically closer to 
new technologies may be able to evaluate and access these technologies earlier. Would the use of 
alliances reduce the time lag between entries of these different firms (Mitchell and Singh, 1992)?  
In order to understand the role of alliances in the search of new technologies, we break 
down the entry of firms into new technologies into parts: through internal development (or 
acquisitions) and through alliances. In the first hypothesis we consider firms’ entry into new 
technologies through internal development without including entry through alliance formation, 
and in the second case, we consider entry into new technologies through alliances: 
 
H1a: When entry through internal development or acquisitions is considered, firms that 
are technologically better endowed are likely to enter these new technologies earlier.  
 
H1b: This gap in timing of entry between firms with different levels of technological 
competences will diminish when entry through alliances is considered.  
 
Alliances and technology internalization 
 
By technology internalization we mean the ability of firms to integrate the technologies 
that they have explored through their alliances within their base of existing capabilities (Helfat 
and Raubitschek, 2000). We propose that there will be significant differences among firms in 
their ability to internalize the technologies from their alliances. Firms with superior technological 
competences will be more likely to internalize and retain the technologies from their alliance 
investments. This argument is based on several inter-related points. First, the existing 
technological competencies provide better access to potential partners, and thus, enable the 
choice of better partners in alliances (Gulati, 1995; Stuart and Podolny, 1996). Second, superior 
technological competences lead to better absorptive capacity (Cohen and Levinthal, 1990). Third, 
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firms with weaker technological capabilities are likely to possess dense and narrow portfolios of 
alliance technologies, which can be “sub-additive” (Vassolo, Anand and Folta, 2004). Such 
portfolios may suffer from significant redundancies and overlaps among technological and 
market opportunities pursued in alliances (Katila and Ahuja, 2002). This implies that firms are 
less likely to assimilate a large number of technologies given that even a large number of 
alliances expose them to only a few technologies. Based on these arguments, we conclude that: 
 
H2a: Existing technological competences positively affects the internalization of the new 
technologies accessed through alliances  
 
While, as the above hypothesis argues, technological competence may have a positive 
effect on the internalization of new technologies, this effect may not be homogenous at different 
levels of competencies. Specifically, beyond a certain level of technological competence this 
effect may begin to plateau in keeping with the standard diminishing returns arguments. 
Therefore: 
  
H2b: Existing technological competences have a decreasing marginal effect on the 
internalization of the new technologies accessed through alliances 
  
Notice that the dependent variable in the hypothesis is not only about the internalization 
of alliance capabilities through a buy-out of the partner, but can also involve assimilation of 
alliance capabilities through learning. This is important because under certain conditions, the firm 
may choose to invest in learning from the partner, followed by a divestiture of the alliance 
(Hamel, 1991). Since both mechanisms of internalization are included here, it is a better 




Biotechnology research involves many technological domains, which we have referred to 
as 'technologies' throughout the paper. There are about 150 such biotech domains. Examples of 
technological domains used in this study are AIDS Therapeutics, DNA Probes, and Vaccines.   
 
Data 
We test the above hypotheses using data on biotech investments made by pharmaceutical 
firms. The main source of information about technological distances and overlapping, equity 
agreements, acquisitions, and divestitures is BioScan. Biotechnology research involves many 
kinds of technological domains, which we have referred to as 'technologies' throughout the paper. 
There are about 150 such biotech domains. Examples of technological domains used in this study 
are AIDS Therapeutics, DNA Probes, and Vaccines.   
Data collected include all the equity agreements and outright acquisitions made by the 
largest worldwide 30 pharmaceutical companies – hereafter, ‘firms’ - with biotech labs between 
1989-1999.  These thirty firms come from several different countries, including USA, England, 
France, Germany, and Switzerland. The final sample includes 448 R&D based equity 
transactions: 364 minority equity investments in biotechnology labs, 22 outright acquisitions of 





Dependent Variables   
Our study deals with two different dependent variables corresponding to the different 
hypotheses. In the hypotheses H1a and H1b, the analysis involves timing of entry. In this case, 
the dependent variable is defined as the timing of the exercise event – i.e., the timing of the first 
investment in each technology by each firm. As concerns H2, internalization of alliance 
technologies involves internalization of a technology within an alliance in which the firm is not 
already investing. This can be achieved by either acquiring the alliance partner or investing in this 
technology internally (learning) while keeping the alliance. The dependent variable is defined as 
the timing of the exercise event, and it is coded “1” if the focal firm internalizes a technology and 
“0” otherwise.  
 
Independent Variable 
In order to test our hypotheses, we include a measure of technological competence of 
firms. Following a consolidated approach (e.g., Narin, Noma and Perry, 1987), we use patent data 
to build this measure. We gathered patent information from the NBER database. For each year 
and firm in the sample, we calculated the cumulative stock of patents.    
 
Control Variables 
This study uses a measure of organization size for control for the financial resource 
position: total pharmaceutical annual sales, in US$ millions.  The number of firm technologies is 
a proxy of the technological domains that the pharmaceutical incumbent is investigating 
(Rothaermel, 2001).  This study proposes the number of firm alliances established in the history 
of the pharmaceutical company as a control variable for firm’s absorptive capacity (Sarkar, 
Echambadi, and Harrison, 2001).  The attractiveness of investment in biotech is controlled for by 
industry returns, which is based on the biotechnology industry index adjusted by the risk-free 
interest rate. We use an indicator variable approximate the degree of appropriability of the 
partnership: license.  Interest rates influence the opportunity cost of an investment.  Interest is 
measured using the one-year Treasury Bill rate. 
 
Statistical Analyses 
In our empirical analysis we use hazard rate models. The Gompertz distribution was 




In general, our results provide support for our hypotheses. Hypotheses 1a is supported: 
firms with greater number of patents are likely to enter new technologies earlier, since the 
coefficient of the number of patents is positive and statistically significant at the 1% level. Our 
results also support hypothesis 1b: the coefficient corresponding to the measure of technological 
competence is negative and statistically significant at the 0.1% level. This result suggests that 
firms with greater technological capabilities tend to enter new technologies earlier through 
internal development (or acquisitions) and firms that are less technologically competent tend to 
catch up using alliances.  
In hypotheses 2a and 2b we had suggested that firms technologically better endowed 
would be more likely to internalize technologies accessed through alliances, even though the 
marginal effect would be decreasing with the level of technological competence. When we test 
the linear effect of the number of patents, we do not obtain a statistically significant coefficient, 
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although the Likelihood Ratio test indicates that the addition of this variable provides significant 
explanatory power (p < 0.001).  When the non-linearity predicted by H2b is accounted for, we 
obtain results fully supporting H2a and H2b. The first order coefficient of the number of patents, 
in fact, has a positive and statistically significant coefficient (0.1%), suggesting that a higher 
number of patents favor technology internalization. This implies that the number of patents has a 
marginal decreasing effect on internalization.   
 
CONCLUSIONS AND DISCUSSION 
 
 Previous research has documented that technological or capability development is often 
path dependent, and alliances can serve as a dynamic capability for firms that are less 
technologically competent. In this sense Alliances are particularly important when firms are faced 
with a technological discontinuity and search for new technologies. Our results confirm that 
alliances are used to access new technological competencies, but also reveal the difficulty in 
internalizing new technology for such firms.   
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